Search
for
Sort by
Research 31–60 of 326
- The Rotterdam Study: 2018 update on objectives, design and main results
- K channel therapeutics at the bedside
- Skin steroidogenesis in health and disease
- Adverse health effects of androgen use
- Potassium channel openers: therapeutic potential in cardiology and medicine
- Protective cardiovascular and renal actions of vitamin D and estrogen
- Psychotropic Medications and the Skin
- Effects of local and systemic medications on eye health: Adverse reactions
- Tinea Capitis: A Practical Approach
- General Dermatology
- Cytostatics and immunosuppressive drugs
- Used Right, IV Arsenic Is Safe & Effective
- SAT-LB82 Myxedema as Presenting Feature of Profound Primary Hypothyroidism in a Toddler
- Nitrogen‐Boosted H <sub>2</sub> O <sub>2</sub> Production of Arginine‐Polyphenol Nanozyme Drives Oxidative Eustress for Hair Regeneration
- The Rotterdam Study: objectives and design update
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- COVID-19: Pulmonary and Extra Pulmonary Manifestations
- Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
- Long-Term Effects of COVID-19
- Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents
- Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Rash morphology as a predictor of COVID‐19 severity: A systematic review of the cutaneous manifestations of COVID‐19
- COVID-19: The question of genetic diversity and therapeutic intervention approaches
- Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
- Low-Dose Oral Minoxidil During Chemotherapy: A Review of the Mechanism and Current Evidence
- A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia
- Systemic Antifungals
- The significance of the apelinergic system in doxorubicin-induced cardiotoxicity
- Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir